|Bid||0.00 x 1100|
|Ask||0.00 x 1000|
|Day's Range||18.04 - 19.44|
|52 Week Range||8.39 - 23.91|
|Beta (5Y Monthly)||1.22|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 08, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||46.00|
Subscribe to Yahoo Finance Plus to view Fair Value for ANVS
The mean of analysts' price targets for Annovis Bio, Inc. (ANVS) points to a 178.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here is how McKesson (MCK) and Annovis Bio, Inc. (ANVS) have performed compared to their sector so far this year.
Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's and Parkinson's disease announced today the filing of a patent application that extends the breadth of its platform from neurodegenerative to neuropsychiatric indications: "Treatment of mental illness via administration of buntanetap and analogues."